Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2009

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global Growth Conference in Boston on August 12, 2009 at 10:30 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
2. InterMune to Release Second Quarter Financial Results on August 6
3. InterMune to Present at Goldman Sachs Healthcare Conference
4. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
5. InterMune to Release First Quarter Financial Results on April 30
6. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
7. InterMune to Present at Canaccord Adams Hepatitis C Conference
8. InterMune to Present at Citis 4th Annual Biotech Day
9. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
10. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
11. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... 2017 , ... Spectral imaging is a non-destructive technique used ... unique capability combines high resolution imaging with spectral analysis. The system is ... chemical analysis, quality control, and decision-making. , Snapshot spectral imaging is key for ...
(Date:7/26/2017)... -- Nurse practitioners play a crucial role in helping patients decode ... Manuals survey released today. The survey of 210 NPs, ... percent) believe they spend at least half of appointment times ... ... survey of 210 nurse practitioners finds that 78% of NPs ...
(Date:7/24/2017)... ... July 24, 2017 , ... Charm Sciences, Inc. is pleased ... the National Conference on Interstate Milk Shipments (NCIMS) Laboratory Committee and Appendix N Committee ... launch July 1, 2017. , The NCIMS voted at its annual meeting in April, ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Arnold and Mabel ... Professor of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology, ... award recognizes an individual who has made and is continuing to make significant ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):